A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Clinical trial NCT05384626 · RECRUITING

Trial details

NCT number: NCT05384626
Sponsor: Nuvalent Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced Solid Tumor Metastatic Solid Tumor

Start date: 2022-06-09
Primary completion: 2027-12-01
Enrollment: 840

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.